Erythrocyte insulin receptors were studied in nine children treated with prednisone (2 mg/kg body weight/day) for various diseases. Two children were treated for 7 days and the other seven for 14 days. Fasting blood glucose rose slightly but significantly insulin specifically bound to 4.4 x lo9 cells, rose from 10.7 + 1.7% before to 16.1 + 4.0% after 7 days of prednisone therapy (means + S.D., P < 0.025). This rise was accounted for by a 2-fold increase in the number of receptors per cell (from 54 + 11 before to 97 + 25 after 7 days of treatment, means + S.D., P < 0.05), with no detectable change in receptor affinity. This alteration in the number of erythrocyte receptors was observed throughout the period of prednisone administration, and was reversed 5 days after prednisone withdrawal. The development of insulin resistance despite the increase in the number of insulin receptors suggests that prednisone alters the cellular mechanism(s) of insulin action at a step (or steps) distal to the insulin receptor.
Carbohydrate intolerance is a well established consequence of glucocorticoid excess, that can occur spontaneously (27, 35, 36) or in response to exogenous glucocorticoid administration in man (8, 26) or in animals (1) . This glucocorticoid-induced glucose intolerance is related to an insulin-resistant state which is manifested by a varying degree of hyperglycemia in the face of hyperinsulinemia (26, 27, 34, 36) . It was first thought that the effect of glucocorticoids could be accounted for mainly by increased gluconeogenesis (22) . In fact, glucocorticoids seem both to increase hepatic glucose output and to inhibit peripheral glucose utilization in animals (2, 30) and in man (33) .
The possible role of a glucocorticoid-induced alteration of the insulin receptor has recently been examined. Animal and in vitro studies have led to conflicting results: the effects of glucocorticoids on insulin binding to its receptor were variable, depending on the type of glucocorticoid tested, the cellular model used and the duration of its exposure to steroid (7, 10, 21, 23, 31, 32) . The investigation of insulin binding after glucocorticoid administration to human subjects has also provided ambiguous results (3, 11, 15, 29, 38) . Prednisone administration to normal adult subjects has been shown to increase insulin binding, (3, 29) to have no effect, (15) or to decrease insulin binding (38) . On the other hand, dexamethasone administration is usually accompanied by decreased insulin binding (11, 38) . Such studies have not been reported in children. Indeed, monocytes or adipocytes are not easily accessible for repeated measurements of insulin receptors in children. The method used to measure insulin binding to erythrocyte receptors (20) has been improved (19) and can easily be used in children, even when repeated measures are needed because small amounts of blood are required (24) . In the present study we have investigated the binding of insulin to erythrocytes from children treated with prednisone.
MATERIALS AND METHODS

Patients and protocols.
Nine hospitalized prepubertal children, six girls and three boys aged 1.5-8 years (mean 3.1), were investigated. All had normal weight for height. None was diabetic nor had a family history of diabetes. They were submitted to prednisone treatment (2 mg . kg-'. day-') following two different therapeutic regimes. Two children were treated for 7 days; prednisone was then decreased and stopped within 2 days. Another group consisted of seven children who were treated for 14 days; the dose was then gradually decreased during the next 9 days. Prednisone was administered for the treatment of the following diseases: thrombocytopenia (three cases), pulmonary diseases (four cases) and neurologic disorders (two cases).
Patients were studied after they fasted overnight. A blood sample (5 ml) was collected from all subjects before starting prednisone treatment. In the two children treated for 7 days, fasting blood samples were collected again on day 7 and on day 14. In the other seven children (treated for 14 days), fasting blood samples were collected at day 7, 14, 21, and 28.
The data obtained five days after prednisone withdrawal (i.e., on day 14 for the former two children and on day 28 for the other seven children) were combined and are referred to as "after therapy" data. Informed consent for the drawing of 5 ml of blood was obtained from the parents.
Insulin binding studies. Whole blood (5 ml) was collected into heparinized tubes. Erythrocytes were separated from other blood cells by a modification of the method of Boyum, (6) as reported by Gambhir et al. (19) .
Insulin was iodinated to a specific activity of 250-300 pCi/pg, using a modification referred to as the second modification in ref (18) of the chloramine-T method. The [1251]iodoinsulin was purified on Sephadex G-50 column.
For binding assays, the incubation of red blood cells with insulin and the separation of insulin bound to erythyrocytes from free insulin was performed as described by Gambhir et al. (19) . Degradation of insulin occurring during the binding assay was estimated by 10% trichloroacetic acid precipitation of ['251]insulin in the supernatant buffer (free insulin) at the end of the incubation this degradation was always less than 8% of the total [1251]insulin added originally to the incubation mixture.
Analysis of binding data. All data have been expressed as specific binding of insulin to erythrocytes after subtraction of nonspecific binding. This nonspecific component was determined by a linear regression analysis of the nonsaturable component of binding, using the four highest insulin concentrations tested (ranging from 500-10,000 ng/ml) as previously described (16) . Nonspecific binding ranged from 6-21% of total binding. The concentration of insulin necessary to inhibit 50% of the binding of [125~]insulin (referred to as IC50) was determined from competition curves. The total number of binding sites per cell (referred to as Ro) and the affinity for insulin at low insulin concentration (Re) were derived by Scatchard analysis (37) of the competition curves according to De Meyts and Roth (9) .
~n a l y~c a l~r o c e d u r e s .
Blood cell counts, hemoglobin concentration, and hematocrit were determined in a Coulter counter; a reticulocyte count was performed on each sample. Blood glucose was measured by the glucose oxidase method. Plasma immunoreactive insulin was assayed by the double antibody method (28) .
Statistical analysis. Student's t test for paired data was used to compare results obtained during and after prednisone therapy with those observed before treatment.
RESULTS
Hematologic and biochemical data are presented in Table 1 . Mean red cell count, hemoglobin concentration, and hematocrit were normal and did not vary thoughout the study. Reticulocyte counts (% of total red cells) were not significantly affected by prednisone administration. FBG was found to be slightly but significantly increased on days 7 and 14 of prednisone therapy; on day 21 (corresponding to a decreased dose) FBG was not statistically different, although still slightly elevated from the pretherapeutic value. Five days after prednisone withdrawal, FBG had returned to the pretherapeutic value. Prednisone treatment resulted in a marked (about 100%) increase in fasting plasma insulin, which remained elevated throughout the period of administration of the drug. Plasma insulin returned promptly to the pretherapeutic level after the cessation of prednisone administration (Table  1) .
Insulin binding to erythrocytes was altered during the administration of prednisone. The binding at low insulin concentration (0.1 ng/ml [125~]insulin, referred to as Bo) was increased by about 50% over the pretherapeutic value (Table 2; Fig. 1 ). This increase was observed at day 7 of therapy and was maintained throughout the administration of the drug; Bo returned to the pretherapeutic value shortly (5 days) after cessation of prednisone treatment ( Table 2 ). Competition curves of [1251]insulin binding by unlabeled insulin with erythrocytes obtained before and after 7 days of prednisone administration are depicted in Figure 1 . Insulin binding was increased over a broad range of insulin concentrations in cells from prednisone-treated patients. The concentrations of unlabeled insulin necessary to inhibit 50% of ['251]insulin binding (referred to as IC50) did not vary significantly throughout the study (Table 2 ). Scatchard analysis of these data (before and during prednisone administration) yielded parallel curvilinear plots with different intercepts on the abscissa (Fig. 2) , indicating that in erythrocytes from prednisone-treated patients the increase in insulin binding was accounted for by an increase in total receptor number, rather than by a change in receptor affinity. Accordingly, the calculation from Scatchard plots of total receptor number (Ro) and of the affinity at low receptor occupancy (Re) (9) revealed that Ro was increased in erythrocytes from prednisone-treated patients by 60-90% over the pretherapeutic value throughout the period of drug administration. No significant change was observed for Ke values (Table 2 ). Upon cessation of prednisone treatment, Ro returned to a value that was not statistically different from that observed before therapy (Table 2) .
DISCUSSION
The present study has shown that prednisone therapy in children results in a 60-90% increase in insulin binding to erythrocytes, owing to an increase in the number of insulin receptors. Each value is the mean * S.D. The number of subjects (n) is given at the top of each column. Differences between data obtained during and before treatment are significant where indicated with *P < 0.05; and **P < 0.025. Re (lo8 M-') 2.7 + 0. Table   ? Because insulin binding is influenced by the age of erythrocytes (12, 14, 25) , care was taken to exclude anemic patients with reticulocytosis. Investigated subjects were all prepubertal because variations in insulin binding may also occur during the menstrual cycle (4). In our study, variations in the % of reticulocytes were not significant, although a slight increase was observed at day 14 of prednisone administration (Table 1) . Insulin binding was already enhanced at day 7 (Table 2) , before the slight increase in reticulocytes; moreover, Muggeo et al. (29) have reported that in erythrocytes from normal adults given prednisone, insulin binding is increased irrespective of the mean age of the red cell population, as assessed by the creatine content of erythrocytes. Although we cannot totally exclude the possibility of an effect of prednisone on medullary red cell production, we may reasonably assume that the 60-90% increase in insulin binding which we observed did not predominantly depend on this phenomenon.
In agreement with our results, an increase in the number of insulin receptors has been observed in monocytes from healthy adult subjects given prednisone (3). It has also been recently reported that insulin binding in erythrocytes from normal adults is increased after prednisone administration (29) . In contrast, a decreased insulin binding (due to a decreased receptor affinity) has been observed in erythrocytes of normal adults after prednisone ingestion (38) whereas no change was reported in another study using monocytes (15) . The apparent discrepancy between these results may stem from the duration of prednisone administration; thus, in-the studies where no change (15) , or a decrease (38) , in insulin binding was reported, prednisone was administered for only 3 days (15), or even as a single dose (38) . We, and Muggeo et al. (29) , performed a more prolonged study over several weeks (present study) or months (29) . This duration of prednisone administration may be necessary in order to observe an increase in the number of insulin receptors; however, such an increase was observed on monocytes within a few hours after prednisone intake (3) .
In the present study, the development of a state of insulin resistance in prednisone-treated children is indicated by a 2-fold increase in fasting plasma insulin levels with a concomitant slight increase in fasting blood glucose. Under the conditions of our study, this state of insulin resistance was transient, and was no longer detected within 5 days after cessation of therapy. A striking observation in the face of insulin resistance was the 60-90% increase in the number of insulin receptors, which we observed with erythrocytes from prednisone-treated patients. Insulin-resistant states have been shown to be accompanied by a decreased number (or affinity) of insulin receptors, although with some exceptions (for a review, see ref 5) including the present study. Accordingly, there usually exists an inverse relationship between insulin binding and fasting plasma insulin levels in hyperinsulinemic states ( 9 , which was not found to be the case in the present study where insulin binding increased despite fasting hyperinsulinemia. In human and animal studies, other glucocorticoids such as cortisone and dexamethasone have been shown to cause insulin resistance by interfering at both receptor and postreceptor steps (10, 21) . Insofar as insulin receptors on erythrocytes reflect the status of insulin receptors on major target tissues like muscle, liver, and fat, our results suggest that prednisone-induced insulin resistance results from postreceptor defects. It is not clear at present whether the insulin receptor status of erythrocytes mirrors that of target cells. Binding data obtained with erythrocytes are usually, although not consistently, in good agreement with those obtained with monocvtes (131.
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The mechanism(s) whereby prednisone enhances the number of insulin receptors is (are) presently unknown. In erythrocytes, prednisone may stimulate the biosynthesis of the receptor in immature red cells without altering the number of these cells, although such a mechanism is unlikely because Muggeo et al. (29) have reported that the increase in insulin receptor number occurs irrespective of the cell age. Alternatively, the drug may alter the intracellular traffic of the receptor by inhibiting its internalization (17) , or by favoring its recycling to the cell membrane, or both; however, these processes have thus far not been demonstrated in red blood cells. Further studies will be required to elucidate this peculiar aspect of prednisone action and its consequences on the clinical and hormonal status of the patients treated by this agent.
